These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 31184975)

  • 1. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
    Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
    Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
    J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
    Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
    Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.
    Southwell AL; Skotte NH; Kordasiewicz HB; Østergaard ME; Watt AT; Carroll JB; Doty CN; Villanueva EB; Petoukhov E; Vaid K; Xie Y; Freier SM; Swayze EE; Seth PP; Bennett CF; Hayden MR
    Mol Ther; 2014 Dec; 22(12):2093-2106. PubMed ID: 25101598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
    Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
    Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease.
    Aslesh T; Yokota T
    Methods Mol Biol; 2020; 2176():57-67. PubMed ID: 32865782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
    Caron NS; Byrne LM; Lemarié FL; Bone JN; Aly AE; Ko S; Anderson C; Casal LL; Hill AM; Hawellek DJ; McColgan P; Wild EJ; Leavitt BR; Hayden MR
    Transl Neurodegener; 2024 Oct; 13(1):50. PubMed ID: 39380076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics.
    Fienko S; Landles C; Sathasivam K; McAteer SJ; Milton RE; Osborne GF; Smith EJ; Jones ST; Bondulich MK; Danby ECE; Phillips J; Taxy BA; Kordasiewicz HB; Bates GP
    Brain; 2022 Dec; 145(12):4409-4424. PubMed ID: 35793238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleic Acid Therapeutics in Huntington's Disease.
    Singh K; Roy I
    Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligonucleotides Targeting DNA Repeats Downregulate
    Umek T; Olsson T; Gissberg O; Saher O; Zaghloul EM; Lundin KE; Wengel J; Hanse E; Zetterberg H; Vizlin-Hodzic D; Smith CIE; Zain R
    Nucleic Acid Ther; 2021 Dec; 31(6):443-456. PubMed ID: 34520257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?
    Liu W; Pfister EL; Kennington LA; Chase KO; Mueller C; DiFiglia M; Aronin N
    J Huntingtons Dis; 2016; 5(1):33-8. PubMed ID: 27003665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
    Southwell AL; Kordasiewicz HB; Langbehn D; Skotte NH; Parsons MP; Villanueva EB; Caron NS; Østergaard ME; Anderson LM; Xie Y; Cengio LD; Findlay-Black H; Doty CN; Fitsimmons B; Swayze EE; Seth PP; Raymond LA; Frank Bennett C; Hayden MR
    Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting several CAG expansion diseases by a single antisense oligonucleotide.
    Evers MM; Pepers BA; van Deutekom JC; Mulders SA; den Dunnen JT; Aartsma-Rus A; van Ommen GJ; van Roon-Mom WM
    PLoS One; 2011; 6(9):e24308. PubMed ID: 21909428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs
    Allen S; O'Reilly D; Miller R; Sapp E; Summers A; Paquette J; Echeverria Moreno D; Bramato B; McHugh N; Yamada K; Aronin N; DiFiglia M; Khvorova A
    Nucleic Acid Ther; 2024 Aug; 34(4):164-172. PubMed ID: 39023561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical Modifications and Design Influence the Potency of
    Saher O; Zaghloul EM; Umek T; Hagey DW; Mozafari N; Danielsen MB; Gouda AS; Lundin KE; Jørgensen PT; Wengel J; Smith CIE; Zain R
    Nucleic Acid Ther; 2023 Apr; 33(2):117-131. PubMed ID: 36735581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.